PFS was not statistically different between patients with IDH1/2 mutated 1p19q codeleted gliomas (cyan, 66.9 months; 95% CI: 35.2–110.9) vs. those with IDH1/2 mutations without 1p19q codeletion (navy blue, 44.9 months; 95% CI: 36.3–70.7, Figure 5D). This evidence concerns the gene IDH1 and central nervous system cancer.